



- EDITORIAL, p 7
- FEATURE, p 18
- ANALYSIS, p 24

NEWS

- 1 Poor monitoring and processes are responsible for errors in one in 20 GP prescriptions, report shows
- 2 Kidnapped British health worker is found murdered in Pakistan
“Slick” cigarette packs encourage children to smoke
- 3 Confusion reigns over the role of clinical senates
Internet supplier of fake Viagra is ordered to pay back £14.4m
- 4 Income and satisfaction with medical career fall among US doctors
New BMA council member calls for action to repeal Health and Social Care Act
Social networks and media coverage are blamed for series of teenage suicides in Russia
- 5 Childhood obesity increases blood pressure in adolescence “quite substantially,” study shows
- 6 Fifteen million and rising—number of premature births every year
Indian doctors criticise health ministry’s plan to curb medical “brain drain”



Red Cross health worker Khalil Dale murdered, p 2

RESEARCH

RESEARCH HIGHLIGHTS

- 11 The pick of *BMJ* research papers this week

RESEARCH NEWS

- 12 All you need to read in the other general journals

RESEARCH PAPERS

- 14 Safety and efficacy of antibiotics compared with appendicectomy for treatment of uncomplicated acute appendicitis: meta-analysis of randomised controlled trials Krishna K Varadhan et al
● EDITORIAL, p 8
- 15 Total hip arthroplasty versus resurfacing arthroplasty in the treatment of patients with arthritis of the hip joint: single centre, parallel group, assessor blinded, randomised controlled trial Matthew L Costa et al
● EDITORIAL, p 9
- 16 Diagnostic value of single complete compression ultrasonography in pregnant and postpartum women with suspected deep vein thrombosis: prospective study Grégoire Le Gal et al
- 17 Bullying victimisation and risk of self harm in early adolescence: longitudinal cohort study Helen L Fisher et al

COMMENT

EDITORIALS

- 7 Anti-vascular endothelial growth factor treatment for eye diseases
Ning Cheung et al
● FEATURE, p 18
● ANALYSIS, p 24
- 8 Should conservative treatment of appendicitis be first line? Olaf J Bakker
● RESEARCH, p 14
- 9 Hip resurfacing or stemmed arthroplasty for young active patients? Leela C Biant
● RESEARCH, p 15
- 10 Deep brain stimulation therapy Andres M Lozano



Hip replacement, p 9

FEATURES

- 18 Why using Avastin for eye disease is so difficult
Use of bevacizumab rather than ranibizumab for wet age related macular degeneration could save substantial sums. But, as Ingrid Torjesen reports, the drug company is fighting to protect its profits
● EDITORIAL, p 7
● ANALYSIS, p 24
- 21 Technological approaches to improving care
Kathy Oxtoby introduces the individuals shortlisted for the Transforming Patient Care using Technology award
- 22 What will a doctor bring to the World Bank?
A popular public health doctor has been appointed to the hotly contested position of president of the World Bank. Bob Roehr looks at his credentials and what is expected of him



Jim Yong Kim, p 22

ANALYSIS

- 24 “Not me” drugs for health systems: lessons from age related macular degeneration
The debate surrounding the use of new drugs for age related macular degeneration has sparked worldwide controversy. Robert Campbell and colleagues highlight how differing funding systems have affected use of these drugs
● EDITORIAL, p 7; FEATURE, p 18



Intraocular ranibizumab injection, p 24

Articles appearing in this print journal have already been published on bmj.com, and the version in print may have been shortened. bmj.com also contains material that is supplementary to articles: this will be indicated in the text (references are given as w1, w2, etc) and be labelled as extra on bmj.com.

Please cite all articles by year, volume, and elocator (rather than page number), eg *BMJ* 2012; 344:d286.

A note on how to cite each article appears at the end of each article, and this is the form the reference will take in PubMed and other indexes.



Are mobiles safe? p 27

COMMENT

LETTERS

- 27 Mobile phones and glioma risk
- 28 White rice and type 2 diabetes
- 29 Health literacy; Mathematics is bad for you; Breast implants
- 30 Acute Charcot foot; Cluster headache; On nakedness at work

OBSERVATIONS

ETHICS MAN

- 31 The hardest thing: admitting error Daniel Sokol

VIEWS AND REVIEWS

PERSONAL VIEW

- 32 Terminology confuses the message in UK cancer policy Matthew S Day

BETWEEN THE LINES

- 33 Nothing but wickedness Theodore Dalrymple

MEDICAL CLASSICS

- The diaries of John Knyveton Geoffrey Hooper



A call for consistency in cancer terminology, p 32

OBITUARIES

- 34 George Adams
Created the first purpose built geriatric medical unit in the UK
- 35 Jack Barrow; Kesten Barbara Challen; Henry Bower Kedward; Albert David Manning; Richard Orme; Mora Scott; Peter Alexander Templeton

LAST WORDS

- 47 The psychiatric oligarchs who medicalise normality Des Spence
The golden age of the placebo Colin Brewer

EDUCATION

CLINICAL REVIEW

- 36 Diagnosis and management of haemophilia Karin Fijnvandraat et al

PRACTICE

PRACTICE POINTER

- 41 Perioperative fluid therapy
Rupert M Pearse and
Gareth L Ackland

EASILY MISSED?


- 44 Late onset type 1 diabetes Daniel Lasserson et al

ENDGAMES

- 46 Quiz page for doctors in training

MINERVA

- 48 Surgical theatre efficiency, and other stories




Multimedia

Watch & listen

BMJ's multimedia section offers both videos and weekly podcasts. Watch our **series of short films** about new research and read groundbreaking papers from the *BMJ* archive. Alternatively give your eyes a rest and **listen** to the latest medical news, research, comment, and education.

Visit

bmj.com/multimedia



BMJ

The Editor, *BMJ*
BMA House, Tavistock Square,
London WC1H 9JR

Email: editor@bmj.com
Tel: +44 (0)20 7387 4410
Fax: +44 (0)20 7383 6418
BMA MEMBERS' INQUIRIES
Email: membership@bma.org.uk
Tel: +44 (0)20 7383 6642
BMJ CAREERS ADVERTISING
Email: sales@bmjcareers.com
Tel: +44 (0)20 7383 6531
DISPLAY ADVERTISING
Email: sales@bmjgroup.com
Tel: +44 (0)20 7383 6386

REPRINTS

UK/Rest of world
Email: ngurneyrandall@bmjgroup.com
Tel: +44 (0)20 8445 5825
USA

Email: mfgler@medicalreprints.com
Tel: +1 (856) 489 4446

SUBSCRIPTIONS

BMA Members
Email: membership@bma.org.uk
Tel: +44 (0)20 7383 6642
Non-BMA Members
Email: support@bmjgroup.com
Tel: +44 (0)20 7383 6270

OTHER RESOURCES

For all other contacts:
resources.bmj.com/bmj/contact-us
For advice to authors:
resources.bmj.com/bmj/authors
To submit an article:
submit.bmj.com

The BMJ is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association.

The BMA grants editorial freedom to the Editor of the *BMJ*. The views expressed in the journal are those of the authors and may not necessarily comply with BMA policy. The *BMJ* follows guidelines on editorial independence produced by the World Association of Medical Editors (www.wame.org/wamestmt.htm#independence) and the code on good publication practice produced by the Committee on Publication Ethics (www.publicationethics.org.uk/guidelines/).

The *BMJ* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury, or damage resulting from the use of the *BMJ* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

©BMJ Publishing Group Ltd 2012
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any other means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission, in writing, of the *BMJ*

Published weekly. US periodicals class postage paid at Rahway, NJ. Postmaster: send address changes to *BMJ*, c/o Mercury Airfreight International Ltd Inc, 365 Blair Road, Avenel, NJ 07001, USA. \$796.
Weekly



THE ROYAL COLLECTION/HER MAJESTY QUEEN ELIZABETH II

PICTURE OF THE WEEK

A drawing by Leonardo da Vinci showing the arrangement of the intestines within the abdomen; the liver, stomach and spleen; the appendix, caecum and ileocolic junction (c.1508).

The exhibition, Leonardo da Vinci: Anatomist, is currently being held in the Queen's Gallery of Buckingham Palace until October. It is the largest ever collection of da Vinci's anatomical drawings. Leonardo is recognised as one of the great artists of the Renaissance, but he was also a pioneer in the study of human anatomy and was credited for the first ever sketch of the human appendix. It is believed that he intended to publish his work in a treatise on anatomy, but on his death in 1519, the drawings remained among his private papers.

- EDITORIAL, p 7
- RESEARCH, p 14

RESPONSE OF THE WEEK

"I have also, with my colleagues in service numbering over 100, experienced the stress, uncertainty and demoralisation of being out to tender. Although, like your experience, the threat went away after a prolonged period of time of almost two years, with no explanation, the threat continues to lurk just over the horizon, like a forest fire burning, lighting up the sky. Is it a new dawn or an all consuming deadly conflagration? I, like you, cannot see how this process repeated time and time again is good for patients. The administration costs alone must outweigh any perceived savings and efficiency dies on the altar of cost saving"

Simon Forster, child and adolescent psychiatrist, Tees Esk and Wear Valleys NHS Foundation Trust, Redcar, UK, in response to "Tendering out general practice is bad for doctors—and patients" (*BMJ* 2012;344:e2461)

MOST READ ON BMJ.COM

The effectiveness of SPARX, a computerised self help intervention for adolescents seeking help for depression
Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses
Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD
Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database

BMJ.COM POLL

Last week we asked, "What is the most important change to medical education in the past 20 years?"

1. Debt? 22% (131 votes)
2. Competition to get into medical school? 16% (93 votes)
3. Competition for training posts? 14% (82 votes)
4. Workforce planning? 9% (53 votes)
5. Teaching methods and resources? 40% (238 votes)

Total votes cast: 597

Linked to *Student BMJ*

This week's poll asks: "Should ophthalmologists be encouraged to use bevacizumab to treat age related macular degeneration?"

- FEATURE, p 18

EDITOR'S CHOICE

Avastin versus Lucentis

The bottom line is that ranibuzimab is about 12 times more expensive [than bevacizumab]: the UK could save close to £300m a year if it were standard treatment

Drug treatment for age related macular degeneration is one of medicine's success stories. As Ning Cheung and colleagues explain (p 7), anti-vascular endothelial growth factors are preserving and restoring vision to millions around the world. But a related and less edifying story is stealing the limelight: ranibuzimab (Lucentis) versus bevacizumab (Avastin). It casts a shadow over this great medical advance and puts the world's drug development and licensing systems under the spotlight.

In its anti-cancer drug, bevacizumab, drug developer Genentech has created what may be the world's first "not me" (as opposed to "me too") drug, say Robert Campbell and colleagues (p 22). Despite evidence that it works in macular degeneration, the manufacturers and marketers (Roche in the US, Novartis in the UK and elsewhere) are actively discouraging its use for this condition, even going so far as taking legal action to prevent such off-label use. Why? Because they want people to use their other drug, ranibuzimab, which is licensed for treating macular degeneration.

The bottom line is that ranibuzimab is about 12 times more expensive: Cheung and colleagues report that the UK could save close to £300m (€368m; \$485m) a year if it were standard treatment. So are Roche and Novartis simply fighting to protect their profits? They say no, that they are also protecting patients from the cheaper drug's higher risk profile. Although data from the publicly funded CATT trial in the US found similar effectiveness and safety for the two drugs in treating macular degeneration, the safety of bevacizumab remains a worry. Concerns relate to its greater systemic absorption and the fact that it has to be decanted into smaller quantities for intraocular injection, which introduces the risk of infection.

Whatever the motivation, the company has done all it can to limit the use of bevacizumab outside cancer, most

notably by not applying for regulatory approval for use in patients with macular degeneration. Some health systems are finding ways round this, as Campbell and colleagues explain. But the combination of legal threats, safety concerns, and financial incentives to use ranibuzimab has maintained the more expensive drug's lucrative market. Sales in the US in 2010 topped \$1.8bn.

In the UK, as Ingrid Torjesen reports (p 18), efforts are under way to get bevacizumab approved for use in macular degeneration despite resistance from Novartis. The National Institute for Health and Clinical Excellence has said it could appraise the drug if asked to by the Department of Health. Campbell and colleagues report that the department is waiting for the results of the IVAN trial in the UK, due to be published this month. But it is unlikely to resolve the safety concerns. Neither this nor the CATT trial was big enough to detect small but clinically relevant differences in adverse outcomes such as stroke, they say. Long term postmarketing surveillance is needed for that.

So what's to be done in the best interests of patients and the public purse? Campbell and colleagues call for clear guidance to use bevacizumab from professional organisations, a review of policies that discourage off-label use if there is good evidence for a drug's use, and better communication among health technology assessors in different parts of the world.

Fiona Godlee, editor, *BMJ* fgodlee@bmj.com

Cite this as: *BMJ* 2012;344:e3162

► To receive Editor's Choice by email each week, visit bmj.com/cgi/customalert

Twitter

► Follow the editor, Fiona Godlee, at twitter.com/fgodlee and the *BMJ*'s latest at twitter.com/bmj_latest

**Sign up today using your smartphone**

follow these steps:

- Download a free QR reader from your handset's app store
- Hold your Smartphone over the QR code
- You will then be forwarded to the email sign up page

Join your colleagues.

BMJ Masterclasses

masterclasses.bmj.com

